Investing.com - Guggenheim raised its price target on Assembly Biosciences (NASDAQ:ASMB) to $39.00 from $31.00 on Monday, while maintaining a Buy rating on the stock. The company, currently trading at ...
The average one-year price target for Assembly Biosciences (NASDAQ:ASMB) has been revised to 3.06 / share. This is an increase of 20.00% from the prior estimate of 2.55 dated August 1, 2023. The price ...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback